Head to Head Contrast: BioCryst Pharmaceuticals (BCRX) & Its Rivals

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) is one of 843 public companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare BioCryst Pharmaceuticals to related businesses based on the strength of its dividends, profitability, valuation, risk, earnings, analyst recommendations and institutional ownership.

Valuation and Earnings

This table compares BioCryst Pharmaceuticals and its peers gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
BioCryst Pharmaceuticals $874.84 million $263.86 million -5.25
BioCryst Pharmaceuticals Competitors $715.39 million $10.31 million -18.32

BioCryst Pharmaceuticals has higher revenue and earnings than its peers. BioCryst Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of recent ratings and target prices for BioCryst Pharmaceuticals and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioCryst Pharmaceuticals 1 2 6 0 2.56
BioCryst Pharmaceuticals Competitors 9931 15323 45711 1605 2.54

BioCryst Pharmaceuticals presently has a consensus target price of $20.38, indicating a potential upside of 173.49%. As a group, “Biotechnology” companies have a potential upside of 131.48%. Given BioCryst Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts clearly believe BioCryst Pharmaceuticals is more favorable than its peers.

Profitability

This table compares BioCryst Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioCryst Pharmaceuticals -37.40% -92.91% 66.56%
BioCryst Pharmaceuticals Competitors -12,319.70% -407.93% -30.95%

Volatility and Risk

BioCryst Pharmaceuticals has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals’ peers have a beta of -1.84, indicating that their average stock price is 284% less volatile than the S&P 500.

Institutional and Insider Ownership

85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

BioCryst Pharmaceuticals beats its peers on 11 of the 13 factors compared.

BioCryst Pharmaceuticals Company Profile

(Get Free Report)

BioCryst Pharmaceuticals is a biotechnology company that discovers, develops and commercializes medicines for rare diseases. Founded in 1986, the company is headquartered in Durham, North Carolina, and focuses on small-molecule treatments. Its principal product is ORLADEYO (berotralstat), an oral medicine for preventing attacks of hereditary angioedema, a rare condition that causes episodes of swelling. BioCryst also develops medicines for rare diseases, including candidates targeting hereditary angioedema and complement-mediated disorders.

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.